Plus Therapeutics (PSTV) News Today → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free PSTV Stock Alerts $1.60 -0.03 (-1.84%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePlus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%americanbankingnews.com - April 23 at 1:48 AMMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defensefinance.yahoo.com - April 22 at 10:35 AMPlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defenseglobenewswire.com - April 22 at 7:00 AMPlus Therapeutics, Inc. (PSTV)finance.yahoo.com - April 19 at 12:11 AMNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Teamfinance.yahoo.com - April 9 at 7:57 AMNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.globenewswire.com - April 9 at 7:00 AMPlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conferencefinance.yahoo.com - March 27 at 10:29 AMPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnosticfinance.yahoo.com - March 25 at 8:51 AMBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwindsmarkets.businessinsider.com - March 23 at 7:41 AMPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastasesfinance.yahoo.com - March 11 at 9:16 AMPlus Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 7 at 10:46 AMPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 10:46 AMQ4 2023 Plus Therapeutics Inc Earnings Callfinance.yahoo.com - March 6 at 6:24 PMPSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 5 at 10:33 PMPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlightsglobenewswire.com - March 5 at 4:05 PMIMUNON stock rallies 19% on early results for COVID-19 vaccinemsn.com - February 29 at 1:33 PMPlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024finance.yahoo.com - February 27 at 8:49 AMPlus Therapeutics Inc PSTVmorningstar.com - February 21 at 6:55 PMPlus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024finanznachrichten.de - December 18 at 1:46 PMPlus Updates Financial and Cash Guidance for 2024finance.yahoo.com - December 18 at 8:46 AMPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analysesfinance.yahoo.com - December 12 at 10:20 AMAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)markets.businessinsider.com - November 29 at 8:56 AMFortress Biotech, Plus Therapeutics among healthcare moversmsn.com - November 20 at 2:51 PMPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinarfinance.yahoo.com - November 20 at 9:51 AMPlus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023finance.yahoo.com - November 15 at 10:12 AMAnalysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)markets.businessinsider.com - November 3 at 7:54 AMPlus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastasesfinance.yahoo.com - November 3 at 7:54 AMWhy Plus Therapeutics Stock Popped Todaybenzinga.com - November 1 at 8:10 PMPlus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - November 1 at 10:08 AMPlus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - October 31 at 5:46 PMPlus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinarfinance.yahoo.com - October 25 at 1:40 PMPlus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023finance.yahoo.com - October 23 at 6:40 PMPlus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in Octoberfinance.yahoo.com - October 9 at 7:59 AMTargeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSEfinance.yahoo.com - September 19 at 2:36 PMDirector Howard Clowes Buys 6,993 Shares of Plus Therapeutics Incfinance.yahoo.com - September 15 at 1:27 PMJonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)markets.businessinsider.com - September 11 at 6:55 PMPlus Therapeutics gets $1.9M advance payment from CPRITmsn.com - September 11 at 6:55 PMPlus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conferencefinance.yahoo.com - September 11 at 7:17 AMBiocept gains on licensing pact with Plus Therapeutics for cancer testseekingalpha.com - September 9 at 5:12 PMPlus Fails to Find Traction on Licensing Agreementbaystreet.ca - September 8 at 5:43 PMBiocept (NASDAQ:BIOC) Skyrockets on Licensing Deal with Plus Therapeuticsmsn.com - September 8 at 5:43 PMWhy Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?finance.yahoo.com - September 8 at 5:43 PMPlus Therapeutics Expands Biocept Partnership with Diagnostic Platformfinance.yahoo.com - September 8 at 5:43 PMBiocept Signs CNSide™ Licensing Agreement with Plus Therapeuticsfinance.yahoo.com - September 8 at 8:55 AMPlus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastasefinance.yahoo.com - September 5 at 8:06 AMPlus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 9:23 AMPlus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - August 18 at 3:16 PMPlus Therapeutics Inc.: Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - August 16 at 5:57 AMQ2 2023 Plus Therapeutics Inc Earnings Callfinance.yahoo.com - August 15 at 2:55 PMPlus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - August 14 at 8:24 PM Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 PSTV Media Mentions By Week PSTV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼0.410.43▲Average Medical News Sentiment PSTV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼41▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vivos Therapeutics News Today GBS News Today NeuroMetrix News Today Avinger News Today Titan Medical News Today Venus Concept News Today Minerva Surgical News Today Acutus Medical News Today Sharps Technology News Today Assure News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
